CDSCO approves Astellas' PADCEV for First-Line Advanced Bladder Cancer Treatment
May 21, 2026
Mumbai (Maharashtra) [India], May 21: Astellas Pharma India today announced that PADCEV™ (enfortumab vedotin) in combination with pembrolizumab is now approved for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy in India. This is the first approved combination therapy in India to offer an alternative to platinum-containing chemotherapy, the current standard of care for first-line treatment of advanced urothelial cancer.
Read More...
